Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model

BACKGROUND: Limited efficacy of immune checkpoint blockades was observed in clinical trials in colorectal (CRC) patients, especially in the microsatellite-stable patients. Interleukin-6 (IL-6) is critical in modeling immune responses in cancers. However, the effects of targeting IL-6 in combination...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jibin, Xu, Jian, Yan, Xiaofei, Jin, Keer, Li, Wenya, Zhang, Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2018
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097097/
https://www.ncbi.nlm.nih.gov/pubmed/30087314
http://dx.doi.org/10.12659/MSM.907439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097097/
https://www.ncbi.nlm.nih.gov/pubmed/30087314
http://dx.doi.org/10.12659/MSM.907439

Ejemplares similares